Interaction of Apelin and Angiotensin in the Human Forearm Circulation

What Was Tested

This registered not phased trial tested Apelin.

The apelin-APJ system is a relatively new discovery.

It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

It had two arms (groups): Angiotensin II infusion (experimental) and Noradrenaline (active comparator).

The registry classes the interventions as drug.

Who Took Part

12 planned participants were the target.

It was open to people of any sex aged from 18 years up to 85 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: \> 18 years old.

The full record lists 1 inclusion and 11 exclusion criteria; among the exclusions: lack of informed consent; age \< 18 years,; current involvement in other research studies,.

How the Study Was Run

The set-up was randomized, crossover and double-blind.

Because people in this Apelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Each person switched between Apelin and the comparison at some point, usually with a gap in between.

As a double-blind Apelin study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2009-04 with completion listed for 2010-05.

It ran at 1 site in United Kingdom.

Its stated primary purpose is basic science.

What Was Measured

The main thing measured (primary outcome): Change in apelin mediated forearm blood flow (time frame: 12 months).

It also tracked 1 secondary outcome, for example Change in local and systemic plasma apelin concentration in response angiotensin II infusion.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Apelin in 12 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Apelin compound page, all human trials.